Profile data is unavailable for this security.
About the company
INIFY Laboratories AB is a Sweden-based medical research company that provides cancer diagnostics through laboratory services within pathology. The Company uses a fully digital, standardized and Artificial Intelligence (AI)- supported workflow to optimize quality and response times, initially within prostate. The service includes the whole chain of sample handling: from logistics, to sample preparation, to reporting by a pathologist from either Inify Laboratories or the customer’s organization. INIFY Laboratories' laboratory in Solna, Sweden is intended to provide two types of analyses of prostate Biopsy Specimens to clients: Full pathology Report signed by an INIFY subspecialized pathologist and Whole Slide Images (WSI) generation and result of Pathology Decision Support Tool (PDST) analysis only. The Company origins from ContextVision.
- Revenue in NOK (TTM)3.49m
- Net income in NOK-52.48m
- Incorporated2021
- Employees23.00
- LocationINIFY Laboratories ABScheeles vag 3SOLNA 171 65SwedenSWE
- Phone+46 8267330
- Websitehttps://www.inify.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scandion Oncology A/S | 0.00 | -57.25m | 248.13m | 4.00 | -- | 2.20 | -- | -- | -0.4233 | -0.4233 | 0.00 | 0.2635 | 0.00 | -- | -- | 0.00 | -74.59 | -- | -87.90 | -- | -- | -- | -- | -- | -- | -- | 0.0113 | -- | -- | -- | 48.89 | -- | -- | -- |
| Intervacc AB | 9.08m | -104.52m | 254.19m | 15.00 | -- | 1.13 | -- | 28.00 | -1.40 | -1.40 | 0.1221 | 2.91 | 0.0365 | 3.25 | 1.55 | 595,066.70 | -41.96 | -17.62 | -45.32 | -18.77 | -589.11 | -243.59 | -1,151.30 | -626.90 | 4.33 | -- | 0.0006 | -- | -17.23 | -25.79 | -60.31 | -- | -38.72 | -- |
| Exact Therapeutics AS | 0.00 | -48.33m | 259.85m | 8.00 | -- | 5.76 | -- | -- | -1.51 | -1.51 | 0.00 | 1.41 | 0.00 | -- | -- | -- | -67.21 | -40.21 | -86.14 | -45.67 | -- | -- | -- | -- | -- | -16,578.57 | 0.0258 | -- | -- | -- | -20.52 | -- | -- | -- |
| Arctic Bioscience AS | 33.75m | -45.51m | 261.31m | 20.00 | -- | 1.01 | -- | 7.74 | -1.79 | -1.79 | 1.33 | 10.19 | 0.1075 | 0.7025 | 2.93 | 1,687,501.00 | -14.50 | -- | -16.61 | -- | 28.96 | -- | -134.86 | -- | 2.53 | -- | 0.0079 | -- | -1.52 | -- | -33.77 | -- | -- | -- |
| Aqua Bio Technology ASA | 13.51m | -1.50m | 275.33m | 2.00 | -- | 12.80 | 318.07 | 20.38 | -0.1599 | -0.1599 | 0.4938 | 0.3673 | 0.3079 | 0.6548 | 9.01 | -- | -3.42 | -80.72 | -6.75 | -125.29 | 66.69 | 5.57 | -11.12 | -965.98 | 0.1044 | 0.611 | 0.7538 | -- | 349.88 | 42.04 | 1.97 | -- | -- | -- |
| SynAct Pharma AB | 0.00 | -194.09m | 296.52m | 5.00 | -- | 1.65 | -- | -- | -5.65 | -5.65 | 0.00 | 4.28 | 0.00 | -- | -- | 0.00 | -71.43 | -125.17 | -79.52 | -151.70 | -- | -- | -- | -- | -- | -853.13 | 0.0033 | -- | -- | -- | -117.54 | -- | -- | -- |
| Ultimovacs ASA | 0.00 | -177.88m | 299.33m | 25.00 | -- | 1.15 | -- | -- | -5.17 | -5.17 | 0.00 | 7.53 | 0.00 | -- | -- | 0.00 | -44.31 | -28.80 | -50.09 | -31.12 | -- | -- | -- | -- | -- | -- | 0.0136 | -- | -- | -- | -12.78 | -- | -45.35 | -- |
| Bactiquant A/S | 18.87m | -20.10m | 322.60m | -- | -- | 14.59 | -- | 17.09 | -0.6358 | -0.6358 | 0.5971 | 0.6133 | 0.5055 | 3.67 | 2.83 | -- | -53.83 | -41.26 | -62.59 | -47.16 | -6.14 | 12.89 | -106.51 | -71.77 | 5.43 | -8.54 | 0.0431 | -- | -0.689 | -- | 7.62 | -- | -- | -- |
| Ascelia Pharma AB | 0.00 | -90.27m | 323.76m | 13.00 | -- | 5.23 | -- | -- | -2.63 | -2.63 | 0.00 | 1.80 | 0.00 | -- | -- | 0.00 | -65.17 | -- | -78.39 | -- | -- | -- | -- | -- | -- | -- | 0.2302 | -- | -- | -- | 16.72 | -- | -- | -- |
| INIFY Laboratories AB | 3.49m | -52.48m | 339.27m | 23.00 | -- | 4.55 | -- | 97.17 | -1.16 | -1.16 | 0.0772 | 1.65 | 0.032 | 2.99 | 0.6608 | -- | -48.10 | -- | -48.10 | -- | 76.42 | -- | -1,503.10 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- |
| Lytix Biopharma AS | 3.99m | -87.90m | 362.16m | 10.00 | -- | 5.78 | -- | 90.74 | -2.16 | -2.16 | 0.0981 | 1.26 | 0.0368 | -- | 0.4091 | 399,100.00 | -80.96 | -56.91 | -94.07 | -65.83 | -- | -- | -2,202.36 | -771.78 | -- | -- | 0.0095 | -- | -63.82 | 63.94 | -56.77 | -- | -- | -- |
| Medivir AB | 7.86m | -98.17m | 363.54m | 10.00 | -- | 1.69 | -- | 46.22 | -1.46 | -1.46 | 0.1028 | 1.89 | 0.032 | -- | 1.56 | 773,300.00 | -40.00 | -28.91 | -47.20 | -34.77 | -888.81 | -467.42 | -1,248.18 | -675.96 | -- | -- | 0.0482 | -- | 73.16 | -20.39 | -0.6275 | -- | -47.96 | -- |
| Lifecare ASA | 13.09m | -35.26m | 368.42m | 32.00 | -- | 4.56 | -- | 28.15 | -0.2454 | -0.2454 | 0.092 | 0.4163 | 0.1621 | -- | 4.90 | 408,943.10 | -43.60 | -40.00 | -49.97 | -45.26 | -- | -- | -269.03 | -175.53 | -- | -- | 0.1812 | -- | -40.88 | 30.29 | -101.74 | -- | -- | -- |
| Magle Chemoswed Holding AB | 172.91m | 12.44m | 375.65m | 78.00 | 30.20 | 2.29 | 14.74 | 2.17 | 1.13 | 1.13 | 15.74 | 14.95 | 0.6068 | 0.493 | 8.30 | 2,179,628.00 | 4.36 | 2.52 | 5.86 | 3.52 | 90.58 | 85.67 | 7.19 | 3.92 | 0.6356 | 6.35 | 0.3081 | -- | 17.00 | 9.97 | 33.07 | -- | -6.34 | -- |
| Saniona AB | 21.06m | -84.72m | 394.27m | 23.00 | -- | 14.22 | -- | 18.72 | -1.09 | -1.09 | 0.2629 | 0.2451 | 0.1726 | -- | 5.63 | 900,521.80 | -69.41 | -59.16 | -127.89 | -70.15 | -136.88 | -970.05 | -402.20 | -1,483.55 | -- | -3.85 | 0.71 | -- | 10.19 | -21.05 | 54.71 | -- | -34.94 | -- |
| Herantis Pharma Oyj | 0.00 | 3.20m | 403.71m | 10.00 | 139.22 | 7.46 | 126.08 | -- | 0.0126 | 0.0126 | 0.00 | 0.2344 | 0.00 | -- | -- | 0.00 | 4.31 | -80.46 | 6.16 | -104.37 | -- | -- | -- | -- | -- | -- | 0.0073 | -- | -- | -- | 103.00 | -- | -- | -- |
Data as of Jun 13 2024. Currency figures normalised to INIFY Laboratories AB's reporting currency: Norwegian Krone NOK
8.36%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Danske Bank A/S (Investment Management Sweden)as of 01 Feb 2024 | 2.05m | 4.53% |
| MP Pensjon PKas of 01 Feb 2024 | 1.37m | 3.03% |
| SEB Investment Management ABas of 01 Feb 2024 | 185.44k | 0.41% |
| Aktia Fondbolag Abas of 31 May 2024 | 172.70k | 0.38% |
More ▼
Data from 31 Mar 2024 - 31 May 2024Source: FactSet Research Systems Inc.
